Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Gene variant predicts lymphoma treatment response

German researchers have identified a gene variant that significantly influences the outcome of methotrexate therapy for primary central nervous system lymphoma.

31 Oct 2012

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the European Commission has granted conditional marketing authorisation for ADCETRIS (brentuximab vedotin) for two indications.

31 Oct 2012

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

$Most refractory status epilepticus patients have poor functional outcome$

Most refractory status epilepticus patients have poor functional outcome

Three-quarters of refractory status epilepticus patients have a poor functional outcome, which is linked to drug-induced coma and severe encephalographic suppression, say US scientists.

30 Oct 2012

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL).

30 Oct 2012

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to destroy heart tissue, as well as tumors, in some patients.

29 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

John Theurer Cancer Center, LRF to host Ask the Doctor About Lymphoma

The Lymphoma Research Foundation (LRF), the nation's largest non-profit organization devoted to lymphoma research, is partnering with John Theurer Cancer Center, one of the nation's 50 best hospitals for cancer, to bring the lymphoma community information about the rapidly changing world of lymphoma treatment.

23 Oct 2012

R848 chemical can prime the immune system to fight lymphoma

UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

From The University of Manchester 20 Oct 2012

NIH honors Scripps Florida postdoctoral fellow with Pathway to Independence Award

The career of Antonio (Tony) Amelio, a postdoctoral fellow in the Department of Cancer Biology at The Scripps Research Institute, has gotten a boost from the National Institutes of Health in the form of a Howard Temin Pathway to Independence Award in Cancer Research.

17 Oct 2012

Night work can increase risk of cancer in men

Night work can increase cancer risk in men, according to a new study published in the American Journal of Epidemiology by a research team from Centre INRS-Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Universit- de Montr-al.

16 Oct 2012

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Reproducing a rare type of B cell in the laboratory and infusing it back into the body may provide an effective treatment for severe autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, according to researchers at Duke University Medical Center.

15 Oct 2012

Comparing animal and human cancer is of mutual benefit

A diagnosis of cancer once spelled the end for our animal companions but the launch today of a specialty cancer clinic, led by one of Australia’s leading veterinary oncologists at the University of Sydney, offers new hope.

14 Oct 2012

LLS symposium to review latest advances in blood cancer research

A cadre of leading researchers in hematology, oncology, cell biology, and biotechnology are conducting presentations and discussions at this symposium to review the latest advances in blood cancer research.

12 Oct 2012

Researchers develop interference therapies to knock down gene that drives MCL

Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.

From Integrated DNA Technologies 11 Oct 2012

Women respond much better than men to treatment of CFL with rituximab

Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the highly respected journal "Haematologica".

11 Oct 2012

Lymphoma News and Research

Further Reading

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

CD22 protein could prove to be important new target for anti-cancer therapy

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Gene variant predicts lymphoma treatment response

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Most refractory status epilepticus patients have poor functional outcome

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

John Theurer Cancer Center, LRF to host Ask the Doctor About Lymphoma

R848 chemical can prime the immune system to fight lymphoma

NIH honors Scripps Florida postdoctoral fellow with Pathway to Independence Award

Night work can increase risk of cancer in men

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Comparing animal and human cancer is of mutual benefit

LLS symposium to review latest advances in blood cancer research

Researchers develop interference therapies to knock down gene that drives MCL

Women respond much better than men to treatment of CFL with rituximab

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News